Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
Locally Advanced or Metastatic Breast Cancer
DRUG: SPH4336 Tablets 400mg|DRUG: SPH4336 Tablets Placebo
response rate (ORR), tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1., Approximately 3years|Progression-free survival (PFS), from the start date of study treatment to the date of progression disease or death , whichever occurred first., Approximately 3years
Cmax, PK (Pharmacokinetics) parameters, Approximately 3years|Tmax, PK (Pharmacokinetics) parameters, Approximately 3years|Disease control rate (DCR), DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease., Approximately 3years|Duration of remission (DOR), DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response to the date of disease progression per RECIST v1.1 or death from any cause., Approximately 3years|Overall Survival (OS), Determination of the overall survival times of all patients., Approximately 8years|Incidence of Adverse event, Safety and tolerability, Approximately 3years
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer